Houte Hans Van Sells 3,499 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,499 shares of Nurix Therapeutics stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the completion of the sale, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.04, for a total transaction of $16,699.48.
• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24.

Nurix Therapeutics Stock Up 0.4 %

Shares of Nurix Therapeutics stock opened at $12.78 on Friday. Nurix Therapeutics, Inc. has a 1 year low of $4.22 and a 1 year high of $18.12. The stock has a fifty day moving average price of $13.80 and a 200-day moving average price of $9.88.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.04. The company had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. As a group, equities research analysts expect that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Analyst Upgrades and Downgrades

NRIX has been the subject of a number of recent research reports. Royal Bank of Canada boosted their price objective on Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. Robert W. Baird raised their price objective on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Finally, Morgan Stanley raised their price target on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.33.

Institutional Investors Weigh In On Nurix Therapeutics

A number of hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after buying an additional 4,367 shares during the last quarter. Quest Partners LLC bought a new position in shares of Nurix Therapeutics during the 4th quarter worth $59,000. Principal Financial Group Inc. increased its holdings in Nurix Therapeutics by 14.8% in the 3rd quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock worth $122,000 after acquiring an additional 2,002 shares during the last quarter. Jump Financial LLC bought a new stake in Nurix Therapeutics in the 4th quarter valued at about $158,000. Finally, SG Americas Securities LLC purchased a new stake in Nurix Therapeutics during the third quarter valued at about $162,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.